Akorn to acquire VersaPharm for $440 million

10 May 2014

Following swiftly on its completion of the acquisition of Hi-Tech Pharmacal (Nasdaq: HITK) for $640 million in cash (The Pharma Letter April 15), US generics drugmaker Akorn (Nasdaq: AKRK) has entered into a definitive agreement to acquire VPI Holdings, the parent company of VersaPharm, for $440 million in cash.

With its shares having been suspended ahead of the announcement, when trading resumed, Akorn’s stock rose 4% to $25.68 on the acquisition news.

VersaPharm, a privately-held developer and marketer of multi-source (generic) prescription drugs, has a focus in the niche therapeutic categories of dermatology, tuberculosis and hemophilia. VersaPharm has built a robust pipeline of over 20 products, including 11 Abbreviated New Drug Application filed with the US Food and Drug Administration, with an addressable IMS market value of over $700 million. VersaPharm’s expertise in developing topical products complements Akorn’s recently acquired manufacturing platform through the merger with Hi-Tech Pharmacal, the company noted.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK